Hematopoietic stem cells (HSCs) are blood-forming stem cells that produce every type of blood cell in the body: red blood cells, white blood cells and platelets. They are found in bone marrow, in small numbers in circulating blood, and in umbilical cord blood. Doctors use them in stem cell transplants to treat blood cancers, inherited blood disorders and immune system diseases.
Every day, your body replaces billions of blood cells. HSCs make this possible. When they stop working properly, because of a disease like leukaemia or thalassemia, a transplant of healthy HSCs can rebuild the entire blood and immune system.
In this article, you’ll learn what HSCs are, where they come from, how HSC transplants work, which conditions they treat, and why your baby’s cord blood is one of the most valuable sources of these cells.
Hematopoietic stem cells are a type of stem cell responsible for producing all the blood and immune cells in the body. The word “hematopoiesis” comes from two Greek words: haima, meaning blood, and poiesis, meaning to make. HSCs are often simply called “blood stem cells.”
HSCs have two defining abilities:
HSCs are multipotent, not pluripotent. This means they can become any cell within the blood and immune system, but not unrelated cells such as nerve or muscle cells. Pluripotent cells, like embryonic stem cells, can become almost any cell type.
HSCs develop along two main branches:
In the lab, HSCs are identified using a surface marker called CD34. Stem cell banks and transplant centres count CD34+ cells to judge how many usable stem cells a sample contains.
HSCs used in transplants come from three sources: bone marrow, peripheral blood and umbilical cord blood. Each has its own advantages.
| Feature | Bone marrow | Peripheral blood | Umbilical cord blood |
|---|---|---|---|
| How it’s collected | Drawn from the hip bone under anaesthesia | Donor takes injections to move HSCs into the blood, then cells are filtered out (apheresis) | Collected from the umbilical cord after birth; painless for mother and baby |
| When it’s available | Only once a willing, matched donor is found | Only once a willing, matched donor is found | Stored in advance; ready when needed |
| Tissue match needed | Close HLA match | Close HLA match | Less strict match |
| Risk of graft-versus-host disease | Moderate | Higher (especially chronic GVHD) | Lower |
| Main limitation | Invasive collection; finding a donor can take months | Donor needs medication and several hours of apheresis | Fewer cells per unit; blood counts can take longer to recover |
Bone marrow is the body’s main HSC factory and was the first source used for transplants.
Peripheral blood normally has very few HSCs. Donors receive growth-factor injections for a few days to push HSCs from the marrow into the bloodstream. It is now the most common source for adult transplants.
Umbilical cord blood is rich in young, naive HSCs. It can only be collected in the minutes after birth, which is why parents choose to bank their baby’s cord blood. Once frozen, these cells can be stored for decades.
Hematopoietic stem cell transplantation (HSCT) replaces a patient’s diseased or damaged blood-forming cells with healthy HSCs. It is often called a stem cell transplant or, when the cells come from marrow, a bone marrow transplant.
| Feature | Autologous | Allogeneic |
|---|---|---|
| Whose cells | The patient’s own | A donor’s (a sibling, relative, unrelated donor or cord blood unit) |
| Matching needed | No | Yes, HLA matching |
| Risk of GVHD | None | Present |
| Commonly used for | Multiple myeloma, some lymphomas | Leukaemia, thalassemia, aplastic anaemia, inherited immune disorders |
HLA (human leukocyte antigen) markers are proteins on cells that help the immune system tell “self” from “foreign.” In an allogeneic transplant, the closer the HLA match between donor and patient, the lower the risk of rejection and graft-versus-host disease.
Siblings have a 25% chance of being a full match. Many patients, especially in India, struggle to find a matched unrelated donor. This is one reason cord blood, which tolerates a less strict match, is an important source.
HSC transplants are an established treatment for many serious blood, immune and metabolic conditions. Stem cells are used in the treatment of 80+ conditions, including:
Acute and chronic leukaemias, Hodgkin and non-Hodgkin lymphoma, multiple myeloma and myelodysplastic syndromes. For many of these, an allogeneic transplant offers the best chance of long-term remission.
Thalassemia major and sickle cell disease. A successful allogeneic transplant can be curative, replacing the faulty blood-forming system with a healthy one. Thalassemia is especially relevant in India, which has one of the largest numbers of affected children in the world.
Severe aplastic anaemia and Fanconi anaemia, where the marrow stops producing enough blood cells.
Inherited conditions such as severe combined immunodeficiency (SCID), in which a child is born without a working immune system.
Certain rare conditions, such as Hurler syndrome, where donor cells supply an enzyme the body cannot make.
For some patients with severe, treatment-resistant multiple sclerosis or systemic sclerosis, autologous HSCT is used to “reset” the immune system. This is a specialised option, considered only when standard treatments have failed.
Note: For inherited and genetic conditions, a child’s own cord blood usually can’t be used, because the cells carry the same genetic fault. In these cases, cells from a matched sibling or donor are needed.
HSC transplants can save lives, but they are intensive procedures with real risks. Doctors weigh these carefully against the benefits for each patient.
Immune cells in cord blood are immature and less likely to react against the patient’s body. As a result, cord blood transplants carry a lower risk of severe GVHD than bone marrow or peripheral blood transplants, even with a less complete HLA match.
Cord blood has been used in transplants since 1988 and is now a recognised source of HSCs worldwide. It offers several practical advantages:
Cord blood can only be collected once, at birth. Parents who want to preserve it should plan ahead and choose a cord blood bank before delivery.
The umbilical cord holds two different types of stem cells, and parents often confuse them.
| Feature | Hematopoietic stem cells (HSCs) | Mesenchymal stem cells (MSCs) |
|---|---|---|
| Found in | Cord blood, bone marrow, peripheral blood | Cord tissue (Wharton’s jelly), bone marrow, fat tissue |
| Become | Blood and immune cells | Bone, cartilage, fat and connective tissue cells |
| Current use | Established treatment in transplants for 80+ conditions | Mostly in clinical trials for tissue repair and regenerative medicine |
Banking both cord blood and cord tissue preserves both cell types for the future.
Hematopoietic stem cells are the foundation of the body’s blood and immune system. Through stem cell transplants, they offer a proven treatment for blood cancers, inherited blood disorders and immune deficiencies.
Umbilical cord blood is one of the most accessible sources of these cells. It is quick to use, needs a less strict match and carries a lower risk of GVHD. And because it can only be collected at birth, the decision to preserve it has to be made before your baby arrives.
If you’re expecting, learn more about LifeCell stem cell banking or book a free consultation with our experts. You can also call us at 1800-266-5533.
Hematopoietic stem cells are multipotent. They can develop into all types of blood and immune cells, including red blood cells, white blood cells and platelets, but not into unrelated cell types such as nerve or muscle cells.
HSCs are found mainly in the bone marrow. Small numbers circulate in the bloodstream, and umbilical cord blood is a rich source at birth. All three can be used for stem cell transplants.
Hematopoietic stem cells form blood and immune cells and are found in cord blood and bone marrow. Mesenchymal stem cells form bone, cartilage and connective tissue and are found in cord tissue. HSCs are an established transplant treatment, while MSCs are mainly studied in clinical trials.
The infusion of stem cells is usually painless and is given through a vein like a blood transfusion. However, the overall treatment, including conditioning chemotherapy and recovery, can be demanding and involve side effects.
Yes. Cord blood can be used for a sibling if the HLA match is suitable. Siblings have a 25% chance of being a full match and a higher chance of a partial match, which is often acceptable for cord blood transplants.
When cryopreserved under controlled conditions, cord blood stem cells can be stored for decades. Studies have shown viable cells after more than 25 years of storage.
Are You Family Expecting A Baby?
I authorise LifeCell International Pvt.Ltd & its representatives to contact me with updates and notifications via Email/SMS/WhatsApp/Call. This will override DND/NDNC.